Molecular targeting therapy for renal cell carcinoma

International Journal of Clinical Oncology

Volumn 11, Issue 3, 2006, Pages 209-213

  Eto, Masatoshi ^a   Naito, Seiji ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

BAY 43 9006; Bevacizumab; Carcinoma; Renal cell; SU 11248; VEGF; VHL

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; ERLOTINIB; FLT3 LIGAND; GEFITINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; RAF PROTEIN; SORAFENIB; STEM CELL FACTOR; SUNITINIB; TEMSIROLIMUS; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ASTHENIA; CANCER INHIBITION; CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; DRUG ERUPTION; DRUG TARGETING; DYSPNEA; ENZYME BLOOD LEVEL; FATIGUE; FOOD AND DRUG ADMINISTRATION; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LYMPHOCYTOPENIA; MUCOSA INFLAMMATION; NAUSEA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; REVIEW; STOMATITIS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; HUMANS; IMIDAZOLES; INDAZOLES; INDOLES; KIDNEY NEOPLASMS; PYRIDINES; PYRROLES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIROLIMUS;

EID: 33746127995     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-006-0577-2     Document Type: Review

References (27)

1. RJ Motzer NH Bander DM Nanus 1996 Renal-cell carcinoma N Engl J Med 335 865 875
2. RC Flanigan SC Campbell JI Clark 2003 Metastatic renal cell carcinoma Curr Treat Options Oncol 4 385 390
3. RJ Motzer P Russo 2000 Systemic therapy for renal cell carcinoma J Urol 163 408 417
4. RM Bukowski 2001 Cytokine therapy for metastatic renal cell carcinoma Semin Urol Oncol 19 148 154
5. HF Dvorack 2002 Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy J Clin Oncol 21 4368 4380
6. AIO Kibel JA DeCaprio WG Kaelin Jr 1995 Binding of the svon Hippel-Lindau tumor suppressor protein to Elongin B and C Science 269 1444 1446
7. PH Maxwell MS Wiesener GW Chang 1999 The tumor suppressor protein VHL targets hypoxia-nducible factors for oxygen-dependent proteolysis Nature 399 271 275
8. ME Cockman N Masson DR Mole 2000 Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein J Biol Chem 275 25733 25741
9. O Iliopoulos AP Levy C Jiang 1996 Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein Proc Natl Acad Sci USA 93 10595 10599
10. JR Gnarra S Zhou MJ Merrill 1996 Posttranscriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene Proc Natl Acad Sci USA 93 10589 10594
11. S Kourembanas RL Hannan DV Faller 1990 Oxygen tension regulates the expression of the platelet-derived growth factor-B chain gene in human endothelial cells J Clin Invest 86 670 674
12. JC Yang L Haworth RM Sherry 2003 A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N Engl J Med 349 427 434
13. RJ Motzer MD Michaelson BG Redman 2006 Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma J Clin Oncol 24 16 24
14. RJ Motzer BI Rini MD Michaelson 2005 Sunitinib malate (SU11248) shows antitumor activity in patients with metastatic renal cell carcinoma: updated results from phase II trials Eur J Cancer Suppl 3 227 (abstract 797)
15. SM Wilhelm C Carter L Tang 2004 BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 7099 7109
16. Ratain MJ, Flaherty KT, Stadler WM, et al. (2004) Preliminary antitumor actvity of BAY 43, 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT). ASCO Proc (abstract 4501)
17. B Escudier C Szczylik T Eisen 2005 Randomized phase III trial of the multi-kinase inhibitor Sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC) Eur J Cancer Suppl 3 226 (abstract 794)
18. Rini B, Rixe O, Bukowski R, et al. (2005) AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC). ASCO Proc (abstract 4509)
19. JJ Gibbons C Discafani R Peterson 1999 The effect of CCI-779, a novel macrolide anti-tumor agent, on growth of human tumor cells in vitro and in nude mouse xenografts in vivo Proc Am Assoc Cancer Res 40 301 (abstract 1000)
20. MB Atkins M Hidalgo WM Stadler 2004 Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma J Clin Oncol 22 909 918
21. B Knebelmann S Ananth HT Cohen 1998 Transforming growth factor alpha is a target for the von Hippel- Lindau tumor suppressor Cancer Res 58 226 231
22. L Gunaratnam M Morley A Franovic 2003 Hypoxia inducible factor activates the transforming growth factor-alpha/ epidermal growth factor receptor growth stimulatory pathway in VHL (-/-) renal cell carcinoma cells J Biol Chem 278 44966 44974
23. N de Paulsen A Brychzy MC Fournier 2001 Role of transforming growth factor-alpha in von Hippel- Lindau (VHL) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis Proc Natl Acad Sci USA 98 1387 1392
24. RJ Motzer R Amato M Todd 2003 Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma Invest New Drugs 21 99 101
25. BJ Drucker L Schwartz S Marion 2002 Phase II trial of ZD1839 (Iressa), an EGF receptor inhibitor, in patients with advanced renal cell carcinoma Proc Am Soc Clin Oncol 21 182 (abstract 720)
26. M Beeram EK Rowinsky GR Weiss 2005 A phase II, pharmacokinetic (PK) and biological correlative study of OSI-774 (Tarceva) in patients with advanced renal cell carcinoma, with FDG-PET imaging: evidence of durable stable disease and antitumor activity Eur J Cancer Suppl 2 111 (abstract 369)
27. Spigel DR, Hainsworth JD, Sosman JA, et al. (2005) Bevacizumab and erlotinib in the treatment of patients with metastatic renal carcinoma (RCC): update of a phase II multicenter trial. ASCO Proc (abstract 4540)